Name: Safety and Efficacy of Bispecific Antibodies, ADCs and Combination Therapy
Start: 2023-01-19T10:30+08:00
End: 2023-01-20T17:00+08:00

WP_Post Object ( [ID] => 61470 [post_author] => 7 [post_date] => 2022-08-08 00:13:24 [post_date_gmt] => 2022-08-07 16:13:24 [post_content] => The PepTalk Summit will review clinical successes and milestones of emerging constructs and novel formats for these important assets in the drug development arsenal. The safety and efficacy of bispecifics and ADCs will be examined for molecules in development, and strategies and trends will be shared that address and mitigate toxicity issues. [post_title] => Safety and Efficacy of Bispecific Antibodies, ADCs and Combination Therapy [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => closed [post_password] => [post_name] => safety-and-efficacy-of-bispecific-antibodies-adcs-and-combination-therapy [to_ping] => [pinged] => [post_modified] => 2022-08-08 00:13:24 [post_modified_gmt] => 2022-08-07 16:13:24 [post_content_filtered] => [post_parent] => 0 [guid] => https://globalexpo-net.com/?post_type=event&p=61470 [menu_order] => 0 [post_type] => event [post_mime_type] => [comment_count] => 0 [filter] => raw )